Skip Page Header

Home > Cannabis-based medicinal products.

National Institute for Health and Care Excellence. (2021) Cannabis-based medicinal products. London: NICE. NICE guideline [NG144].

[img]
Preview
PDF (Cannabis-based medicinal products - guidance. November 2019)
134kB
[img]
Preview
PDF (Cannabis-based medicinal products: clarification of guidance - March 2021) - Supplemental Material
48kB

External website: https://www.nice.org.uk/guidance/NG144


This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

 

Recommendations

This guideline includes recommendations on:

 Products covered by the guideline include:

  • cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations
  • the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone
  • plant-derived cannabinoids such as pure cannabidiol (CBD)
  • synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.
Item Type
Report
Publication Type
International, Guideline, Report, Review
Drug Type
Cannabis, Prescription/Over the counter
Intervention Type
General / Comprehensive, Drug therapy, Harm reduction
Date
March 2021
Identification #
NICE guideline [NG144]
Pages
27 p.
Publisher
NICE
Corporate Creators
National Institute for Health and Care Excellence
Place of Publication
London
Edition
Updated edition
EndNote

Repository Staff Only: item control page